TopoTarget enrols patients for trial of leading drug candidate belinostat  

2008.12.19
TopoTarget begins enrolling patients for a phase III trial of its cancer drug candidate belinostat, to be conducted in both North America and Europe
As reported on this website in September, Danish biopharmaceutical company TopoTarget gained fast-track designation from the US Food and Drug Administration (FDA) to conduct a phase III trial of its candidate cancer drug belinostat in peripheral T-cell lymphoma.
 
TopoTarget has now announced in a press release that patient recruitment has opened for the trial, which will enrol approximately 120 patients and will be conducted in both North America and Europe. The trial is designed to establish the efficacy and safety of belinostat. TopoTarget owns the global rights to belinostat, which is the company's lead clinical drug candidate.
 
In the press release, TopoTarget CEO Professor Peter Buhl Jensen expresses pride at initiating a drug trial for a disease with a poor prognosis and for which there is no therapy specifically approved. “This is the first step in accordance with our clinical development plan to bring belinostat to the market as fast as possible. At the same time we are pursuing the steps necessary to bring belinostat to the market in larger indications like solid tumours in combination therapy to fully exploit the clinical and commercial potential of belinostat,” he says.
 
TopoTarget was founded in 2000, and is headquartered in Denmark with subsidiaries in the US, UK, Switzerland and Germany. The company, which currently employs 95 people, focuses on improved treatments for cancer patients and has a late stage clinical pipeline of eight products. TopoTarget has been stock exchange listed since 2005.
 
Link > TopoTarget                 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×